Vertaling van "point of reference for scientific " (Nederlands → Frans) :

The FAMHP wants: ●● To emerge as a point of reference for scientific advice ●● To attract clinical trials ●● To act as rapporteur or RMS in the evaluation of registration applications for important products ●● Where relevant, to be a point of reference
The FAMHP wants: ●● To emerge as a point of reference for scientific advice ●● To attract clinical trials ●● To act as rapporteur or RMS in the evaluation of registration applications for important products ●● Where relevant, to be a point of reference

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Volgens een document van de Europese Commissie met als titel « Laying down harmonised standards for the testing for certain residues in imports from third countries » (document sanco 10318/2003 R5-EN), wordt een waarde van 10 µg/kg aangegeven als referentiepunt voor het ondernemen van een actie (reference points for action) als er geen MRL is.
Selon un document de la Commission Européenne intitulé « Laying down harmonised standards for the testing for certain residues in imports from third countries » (document sanco 10318/2003 R5-EN), une valeur de 10 µg/kg est mentionnée comme point de référence pour une action à entreprendre (reference points for action) lorsqu’il n’existe pas de LMR.

The main points were how to announce the bad news after a suicide, how to deal with the bereaved and whom to refer them to, the first reactions of grief and how to handle one’s own emotions when dealing with the victims.
Les principaux points d’attention étaient comment annoncer la mauvaise nouvelle après un suicide, l’accueil et l’orientation, les premières réactions de deuil et comment les responsables de l’accueil des victimes peuvent gérer eux-mêmes leurs émotions.

Le programme vise à : Apporter un point de contact par téléphone ou par e-mail, assurer un service de support professionnel par téléphone et via un site internet, des consultations face-à-face et une fonction de gestion des cas Référer les médecins demandeurs vers des dispensateurs de soins dans le PHP2, assurant un accès rapide à des spécialistes pour une évaluation approfondie et un traitement si
Le programme vise à : Apporter un point de contact par téléphone ou par e-mail, assurer un service de support professionnel par téléphone et via un site internet, des consultations face-à-face et une fonction de gestion des cas Référer les médecins demandeurs vers des dispensateurs de soins dans le PHP2, assurant un accès rapide à des spécialistes pour une évaluation approfondie et un traitement si nécessaire, incluant un accès immédiat à des structures de prise en charge ambulatoire ou d’hospitalisation si nécessaire Assurer une fonction de gestion de

A national MRSA surveillance program was launched in collaboration with the federal Scientific Institute of Public Health and the reference laboratory for staphylococci (ULB-Erasme) to monitor the prevalence and incidence of MRSA in Belgian hospitals 22 and a decrease was observed after more than 80 % of the hospitals had adopted the national guidelines.
Un programme national de surveillance de MRSA a été lancé en collaboration avec l'Institut scientifique fédéral de Santé publique et le laboratoire de référence pour les staphylocoques (ULB-Erasme) afin de surveiller la prévalence et l’incidence de MRSA dans les hôpitaux belges 22 .

Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.
Encouraging clinical trials and the inherent evaluation of applications for these trials, as well as the creation of a scientific subgroup for oncology, means that the FAMHP will need to have the necessary autonomy to attract the essential expertise for this relatively complex domain from the point of concept of innovative medicines.